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Pulmonary Langerhans cell histiocytosis, also called pul-monary histiocytosis X, is an uncommon interstitial lung 
disease that primarily affects young adults with history of cur-
rent or past smoking. Several case reports and case series have 
shown the increased risk of various malignancies including 
lung adenocarcinoma in patients of pulmonary Langerhans 
cell histiocytosis.1–3
CASE REPORT
A previously healthy 28-year-old woman with 10-pack-year 
smoking history presented to our hospital with generalized 
tonic-clonic seizure. Magnetic resonance imaging of the brain 
showed a partially cystic and partially solid left frontal lobe 
mass lesion (Fig. 1). The patient underwent a surgical resec-
tion of the lesion, and pathological examination of the lesion 
was consistent with adenocarcinoma (AC) of unknown ori-
gin. We ordered a positron emission tomography–computed 
tomography scan to look for the primary site of the AC, 
which showed a hypermetabolic left upper lobe lung mass 
with hypermetabolic activity in the left hilar region (Fig. 2). 
A computed tomography scan of the thorax was done subse-
quently, which showed the left upper lobe lung mass (2.7 cm × 
2.1 cm) with hilar lymphadenopathy (Fig. 2) and innumerable 
bizarre shaped, disorganized cystic lung lesions consistent 
with the diagnoses of pulmonary Langerhans cell histiocyto-
sis (PLCH) (Fig.3). A computed tomography–guided biopsy 
of the left upper lobe lung lesion was done, which was consis-
tent with diffusely infiltrating AC of the lung (Fig. 4). Biopsy 
specimen was tested for two most common types of somatic 
epidermal growth factor receptor mutations, exon 19 dele-
tion and exon 21 L858R point mutation, both of which were 
absent. Fluorescence in situ hybridization analysis of tumor 
specimen showed absent anaplastic lymphoma kinase (ALK) 
rearrangement on chromosome 2p23 but interestingly showed 
amplification of ALK signal in 58.5% of the analyzed cells. 
The patient was started on cisplatin and pemetrexed for the 
treatment of primary metastatic lung AC.
DISCUSSION
PLCH is a rare interstitial lung disease pathologically char-
acterized by an abnormal proliferation of Langerhans cells, 
cyst formation, and vascular abnormalities. Usual age range 
of PLCH patients is between 20 and 40 years of age, and more 
than 90% of cases are either current or previous smokers. 
Association between bronchogenic carcinoma and PLCH has 
been reported in few case series and case reports, but overall 
it is rare and quite unusual. Sadoun et al.1 reported five bron-
chogenic carcinoma cases in a series of 93 PLCH patients; 
Vassallo et al.2 reported five primary lung cancers in a series 
of 102 cases with PLCH, and Lombard et al.3 reported four 
lung cancer cases of 130 pulmonary PLCH patients.
The hypotheses of increased risk of bronchogenic carci-
noma in lung scar tissue caused by fibrosis in PLCH plus the 
fact that most of PLCH patients are current smokers or have 
a history of smoking and combination of the both are thought 
to be the underlying causes of increased incidence of lung 
carcinoma in PLCH patients. Scar carcinomas are usually 
peripheral in location.4 Most of these carcinomas are located 
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in upper lobes, and more than 70% of them are ACs. The 
peripheral location of the lung AC in our case does support 
this hypothesis but other case series and reports have reported 
central as well as lower lobe bronchogenic carcinomas in 
association with PLCH.1 Presence of epidermal growth fac-
tor receptor mutations and ALK gene rearrangements in non–
small-cell lung cancer have better prognostic values because 
of newer targeted therapies; however, the significance of ALK 
gene amplification frequently found in many non–small-cell 
lung cancers is currently unclear.
CONCLUSION
This case reemphasizes the importance of keeping a close eye 
for the detection of bronchogenic lung carcinoma in PLCH 
patients, especially given the young age of our patient at the 
time of diagnosis. It is thus important to note that smoking can 
have major consequences even in younger people.5
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FIGURE 2. A, Positron emission 
tomography scan of the chest showing 
hypermetabolic left upper lobe lung 
mass and left hilar mass; (B) corre-
sponding computerized tomographic 
scan of the chest showing the same 
masses with some cystic parenchymal 
lung lesions.
FIGURE 3.  Computerized tomographic scan of the chest 
showing innumerable cysts consistent with pulmonary 
Langerhans cell histiocytosis.
FIGURE 4.  Microscopic examination of the lung mass 
biopsy specimen consistent with moderately differentiated 
lung adenocarcinoma.
